Zobrazeno 1 - 10
of 578
pro vyhledávání: '"NT Ueno"'
Autor:
Rie K. Tahara, JM Reuben, Babita Saigal, Beth Chasen, Diane Liu, Gabriel N. Hortobagyi, T Fujii, Debu Tripathy, Senthil Damodaran, Bora Lim, NT Ueno, Hui Gao, Nuhad K. Ibrahim, Anthony Lucci, Yu Shen
Publikováno v:
Cancer Research. 79:P1-18
Background: Radium-223 dichloride (Ra-223) is a targeted alpha particle-based radiotherapeutic that has a localized cytotoxic effect on bone metastases. We sought to determine whether the circulating tumor cell (CTC) count and the presence of CTCs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be4bd460283b719ce6b66a27ea43211f
https://doi.org/10.1158/1538-7445.sabcs18-p1-18-04
https://doi.org/10.1158/1538-7445.sabcs18-p1-18-04
Autor:
Chandra Bartholomeusz, JM Reuben, Debu Tripathy, Venkata Lokesh Battula, Gaurav B. Chauhan, John W. Park, NT Ueno, Evan N. Cohen
Publikováno v:
Cancer Research. 79:P2-06
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by a high rate of metastatic recurrence and poor prognosis. Molecular mechanism underlying the metastatic behavior of TNBC has not been well eluc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50d27b6a9abcb722a5f9df7d29d5ffd9
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-22
https://doi.org/10.1158/1538-7445.sabcs18-p2-06-22
Autor:
V. Valero, Tanya W. Moseley, A Al-Awadhi, M Kono, Huiying Sun, Jie Willey, M Fu, Bora Lim, Angela N. Marx, Gary J. Whitman, NT Ueno
Publikováno v:
Cancer Research. 79:OT2-07
Background: Neratinib, a potent irreversible pan-ErbB tyrosine kinase inhibitor that blocks signal transduction through HER1, HER2, and HER4, has demonstrated activity against metastatic HER2-positive breast cancer (HER2+ BC) in patients pretreated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fa58aed145d618d5df61733740f1f39
https://doi.org/10.1158/1538-7445.sabcs18-ot2-07-09
https://doi.org/10.1158/1538-7445.sabcs18-ot2-07-09
Autor:
Akshara Singareeka Raghavendra, Debu Tripathy, S. L. Moulder, Ravi Murthy, Carlos H. Barcenas, Sharon H. Giordano, Alastair M. Thompson, EA Mittendorf, Bora Lim, Mariana Chavez-MacGregor, V. Valero, Jennifer K. Litton, KR Hess, NT Ueno
Publikováno v:
Cancer Research. 79:P6-17
Background: Pertuzumab (P) in combination with trastuzumab (H) based chemotherapy is FDA-approved as a standard neoadjuvant treatment for patients with clinical stage II-III HER2-positive (HER2+) breast cancer (BC). The goal of this study was to eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75d9a8c0165b1302b65f621a57ea1e40
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-04
https://doi.org/10.1158/1538-7445.sabcs18-p6-17-04
Autor:
V. Valero, Beatriz E. Adrada, Michael Z. Gilcrease, Rosalind P. Candelaria, Debu Tripathy, Senthil Damodaran, Rachel M. Layman, Lumarie Santiago, Alastair M. Thompson, Lei Huo, Gabriel N. Hortobagyi, S. L. Moulder, Ravi Murthy, Bora Lim, Helen Piwnica-Worms, Fraser Symmans, KR Hess, Carlos H. Barcenas, EA Mittendorf, Wei Tse Yang, Gaiane M. Rauch, Akshara Singareeka Raghavendra, Clinton Yam, NT Ueno, Thorunn Helgason, Jennifer K. Litton
Publikováno v:
Cancer Research. 79:P1-15
Background: Serial biopsies (bx) of triple-negative breast cancer (TNBC) in the curative neoadjuvant setting provides critical information on dynamic changes in the tumor in response to neoadjuvant systemic therapy (NAST) and can help inform the deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8d45cd202713f245aa4f22bee9b2f7a
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-06
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-06
Autor:
Kumiko Kida, Aysegul A. Sahin, Bora Lim, Debu Tripathy, Huey Liu, June G. Lee, NT Ueno, Ravi Murthy
Publikováno v:
Cancer Research. 79:P3-10
Background: Although tremendous progress has been achieved with targeted therapy for HER2-positive (HER2+) metastatic breast cancer, most advanced tumors eventually develop resistance. Improving our understanding of mechanisms of resistance to anti-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::449e31ff75ca026327c28adaff22b724
https://doi.org/10.1158/1538-7445.sabcs18-p3-10-23
https://doi.org/10.1158/1538-7445.sabcs18-p3-10-23
Publikováno v:
Cancer Research. 79:P5-17
Background: Inflammatory breast cancer (IBC) is the most lethal and aggressive form of breast cancer and there are no approved targeted therapies specifically for IBC. Targeting the epidermal growth factor receptor (EGFR) pathway is a promising thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c9c945b8f4c29fe63f5b8424e0d3fdf
https://doi.org/10.1158/1538-7445.sabcs18-p5-17-06
https://doi.org/10.1158/1538-7445.sabcs18-p5-17-06
Autor:
Maarten Slagter, Marleen Kok, Amy B. Heimberger, Eric Jonasch, NT Ueno, Sy Lin, Renata Ferrarotto, Patrick G. Pilie, Bora Lim, Jeffrey T. Chang, S. L. Moulder, Naim U. Rashid, Jennifer K. Litton, Mustafa Khasraw, Leonie Voorwerk, Daniel J. McGrail
Publikováno v:
Ann Oncol
BACKGROUND: High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB), largely due to potential for tumor mutations to generate immunogenic neoantigens. Despite recent pan-cancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af97ce55b22ce67fc814c18718080f7a
https://europepmc.org/articles/PMC8053682/
https://europepmc.org/articles/PMC8053682/
Autor:
Lei Huo, William Fraser Symmans, Rosalind P. Candelaria, NT Ueno, Thorunn Helgason, KR Hess, Jennifer K. Litton, Helen Piwnica-Worms, Bora Lim, S. L. Moulder, Ravi Murthy, Michael Z. Gilcrease, Beatriz E. Adrada, Wei Tse Yang, Gaiane M. Rauch, Clinton Yam, Lumarie Santiago, Senthil Damodaran, Elizabeth A. Mittendorf, Alastair M. Thompson
Publikováno v:
Cancer Research. 78:P1-07
Background: Gene expression profiling (GEP) has identified several molecularly distinct subtypes of triple negative breast cancer (TNBC). Currently, GEP-based molecular diagnostics are not routinely used in clinical decision making due to the lack of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8fd02347a8f25f45d526882a2630d07f
https://doi.org/10.1158/1538-7445.sabcs17-p1-07-22
https://doi.org/10.1158/1538-7445.sabcs17-p1-07-22
Autor:
Anjali James, Charles Mylander, JR Espinosa Fernandez, Lorraine Tafra, Rubie Sue Jackson, Arup Kumar Sinha, Martin Rosman, Michele M. Gage, Takeo Fujii, Akshara Singareeka Raghavendra, F Le Du, NT Ueno
Publikováno v:
Cancer Research. 78:P3-09
Introduction: The 21-gene recurrence score (RS) assay categorizes hormone receptor positive, node negative breast cancers (BC) into 3 risk groups for recurrence. We previously showed that the AAMC Model, using only standard pathology data, accurately
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f2f972bbc3061f8cc060f8b1a1f855
https://doi.org/10.1158/1538-7445.sabcs17-p3-09-05
https://doi.org/10.1158/1538-7445.sabcs17-p3-09-05